HDM2 protein overexpression and prognosis in primary malignant melanoma.
HDM2 protein overexpression and prognosis in primary malignant melanoma.
复制标题
DOI：
10.1093/jnci/94.23.1803
复制
发表时间：
2002-12
期刊：
影响因子：
--
通讯作者：
D. Polsky;K. Melzer;Carole Hazan;K. Panageas;K. Busam;M. Drobnjak;H. Kamino;J. Spira;A. Kopf;A. Houghton;C. Cordon-Cardo;I. Osman
中科院分区：
文献类型：
--
作者：
D. Polsky;K. Melzer;Carole Hazan;K. Panageas;K. Busam;M. Drobnjak;H. Kamino;J. Spira;A. Kopf;A. Houghton;C. Cordon-Cardo;I. Osman
在相当大比例的黑色素瘤中观察到癌基因HDM 2的过表达，包括非侵袭性和薄病变，表明HDM 2过表达可能是黑色素细胞转化的早期事件。为了确定HDM 2在黑色素瘤临床进展中的作用，我们检查了其表达是否与患者生存相关。从1972年11月至1982年11月，134例黑色素瘤患者参加了纽约大学黑色素瘤合作组进行了研究，如果有代表性的组织和随访。HDM 2蛋白表达用免疫组织化学方法进行评估。出乎意料的是，我们观察到HDM 2过表达与无病生存率的提高有统计学显著相关。（相对风险[RR] = 0.47，95%置信区间[CI] = 0.24至0.89;双侧卡方检验（2）P = 0.021）和总生存期（RR = 0.55，95% CI = 0.33至0.94;双侧卡方检验（2）P = 0.027）。HDM 2过表达似乎是原发性黑色素瘤患者生存的独立预测因子;然而，需要更大规模的前瞻性研究进行验证。
Overexpression of the oncogene HDM2 is observed in a substantial proportion of melanomas, including noninvasive and thin lesions, suggesting that HDM2 overexpression may be an early event in melanocyte transformation. To determine the role of HDM2 in the clinical progression of melanoma, we examined whether its expression was associated with patient survival. From November 1972 through November 1982, 134 patients with melanoma who participated in the New York University Melanoma Cooperative Group were studied, if representative tissues and follow-up were available. HDM2 protein expression was assessed immunohistochemically. Unexpectedly, we observed that HDM2 overexpression was statistically significantly associated with improved disease-free survival (relative risk [RR] = 0.47, 95% confidence interval [CI] = 0.24 to 0.89; two-sided chi(2) P =.021) and overall survival (RR = 0.55, 95% CI = 0.33 to 0.94; two-sided chi(2) P =.027) in multivariable analysis. HDM2 overexpression appears to be an independent predictor of survival for patients with primary melanoma; however, larger prospective studies are required for validation.